NEW YORK, March 1, 2017 /PRNewswire/ --
On Tuesday, February 28, 2017, the NASDAQ Composite,the Dow Jones Industrial Average, and the S&P 500 edged lower at the closing bell. Eight out of nine sectors ended Tuesday's trading session in bearish territories. Taking into consideration yesterday's market sentiment, Stock-Callers.com assessed
Salt Lake City, Utah headquartered Varex Imaging Corp.'s stock finished Tuesday's session 0.91% lower at $34.82 with a total volume of 663,585 shares traded. The Company's stock has surged 37.03% in the past one month. The Company's shares are trading above its 50-day and 200-day moving averages by 15.16%, each. Shares of Varex Imaging, which designs and manufactures medical X-ray tubes and image processing solutions, are trading at a PE ratio of 19.01. See our free and comprehensive research report on VREX at:
Second Sight Medical Products
Sylmar, California headquartered Second Sight Medical Products Inc.'s stock closed the day flat at $1.67. The stock recorded a trading volume of 351,502 shares. Second Sight Medical Products' shares have gained 19.29% in the last one month. The Company's shares are trading 7.20% and 42.91% below its 50-day and 200-day moving averages, respectively. Additionally, shares of the Company, which develops, manufactures, and markets implantable prosthetic devices to restore functional vision to blind patients in the US, Canada, Italy, France, Germany, Saudi Arabia, and the Netherlands, have a Relative Strength Index (RSI) of 45.86. EYES free research report PDF is just a click away at:
On Tuesday, shares in Irvine, California headquartered Masimo Corp. ended the session 0.19% higher at $90.36 with a total volume of 1.25 million shares traded. Masimo's shares have surged 24.50% in the last one month and 44.35% in the previous three months. Furthermore, the stock has rallied 138.79% in the past one year. Shares of the Company, which develops, manufactures, and markets noninvasive monitoring technologies worldwide, are trading at a PE ratio of 16.18. The stock is trading 23.45% above its 50-day moving average and 49.39% above its 200-day moving average. Moreover, the Company's shares have an RSI of 91.66.
On February 27th, 2017, research firm Wedbush reiterated its 'Outperform' rating on the Company's stock with an increase of the target price from $85 a share to $95 a share. Sign up for your complimentary report on MASI at:
On Tuesday, shares in Redwood City, California headquartered Avinger Inc. recorded a trading volume of 233,985 shares. The stock ended the day 4.08% higher at $2.55. The Company is trading below its 50-day and 200-day moving averages by 15.39% and 54.22%, respectively. Furthermore, shares of Avinger, which designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease in the US and Europe, have an RSI of 47.87. Register for free on Stock-Callers.com and download the latest research report on AVGR at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Steroids are miracle drugs but have to be used with caution. Some steroids are illegal to use, ...
Abruptio placenta is a serious but rare complication of pregnancy where a separation of placenta ...
Cyanosis is the bluish or purplish discoloration of the skin and mucus membranes due to lack of ...View All